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Background: Treatment of pancreatic adenocarcinoma in the elderly is often complicated by comorbidities that
preclude surgery, chemotherapy and/or conventional external beam radiation therapy (EBRT). Stereotactic body
radiotherapy (SBRT) has thus garnered interest in this setting.
Methods: A retrospective review of 26 patients of age ≥ 80 with pancreatic adenocarcinoma treated with definitive
SBRT+/−chemotherapy from 2007–2011 was performed. Twenty-seven percent of patients were stage I, 38% were
stage II, 27% were stage III and 8% were stage IV. Patients most commonly received 24 Gy/1 fraction or 30-36 Gy/3
fractions. Kaplan-Meier was used to estimate overall survival (OS), local control (LC), cause specific survival (CSS) and
freedom-from-metastatic disease (FFMD).
Results: The median age was 86 (range 80–91), and median follow-up was 11.6 months (3.5-24.6). The median
planning target volume was 21.48 cm3 (6.1-85.09). Median OS was 7.6 months with 6/12 month OS rates of 65.4%/
34.6%, respectively. Median LC was 11.5 months, 6-month and 12-month actuarial LC rates were 60.1% and 41.2%,
respectively. There were no independent predictors for LC, but there was a trend for improved LC with prescription
dose greater than 20 Gy (p = 0.063). Median CSS was 6.3 months, and 6-month and 12-month actuarial CSS were
53.8% and 23.1%, respectively. Median FFMD was 8.4 months, and 6-month and 12-month actuarial rates were
62.0% and 41.4%, respectively. Nine patients (47%) had local failures, 11 (58%) had distant metastasis, and 7 (37%)
had both. There were no acute or late grade 3+ toxicities.
Conclusions: Definitive SBRT is feasible, safe and effective in elderly patients who have unresectable disease, have
comorbidities precluding surgery or decline surgery.Background
Pancreatic cancer is the fourth leading cause of cancer-
related deaths in the United States with an estimated inci-
dence of 37,700 cases in 2008 [1]. Effective treatment
remains a challenge, and prognosis remains poor. Most
patients present with disseminated or locally-advanced
disease, and less than 20% present with localized, poten-
tially curable tumors [2]. Even after resections with cura-
tive intent, recurrence is common. The overall 5-year
survival rate among pancreatic cancer patients is less than
5% [1].
Pancreatic cancer is more common in the elderly with
60% of patients presenting at or over the age of 65 [2].* Correspondence: herond2@upmc.edu
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reproduction in any medium, provided the orFurthermore, the population of individuals over 85 years
old experienced the fastest growth rate over the last dec-
ade, increasing by 29.9% [3]. In 2008, this disease was re-
sponsible for 10,779 deaths in patients age 80 and over [4].
These trends warrant the importance of understanding
management of diseases affecting the very elderly such as
pancreatic cancer.
Surgical resection of the pancreas has been shown to
be a safe option for some octogenarians, with rates of
perioperative complications and mortality similar to
those of younger populations [5]. For elderly patients
with unresectable tumors, low-dose gemcitabine may im-
prove prognosis [6]. However, elderly patients may have
significant comorbidities that preclude surgery, chemo-
therapy, or a protracted course of external beam radi-
ation therapy. Stereotactic body radiotherapy (SBRT) is a
promising alternative modality as definitive treatment for. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sults in the treatment of brain and spinal metastases,
early stage bronchogenic cancer, prostate cancer, and
head and neck cancer [7-10]. SBRT treatment for locally-
advanced pancreatic cancer has also been shown to offer
excellent local control with minimal toxicity [11,12]. We
herein report the results of SBRT in the treatment of
pancreatic adenocarcinoma in octogenarians at our insti-




Twenty-six patients age 80 years or greater with
histologically-confirmed adenocarcinoma of the pan-
creas were treated in a definitive setting at our institu-
tion with SBRT between January 2007 and May 2011
(Table 1). Twenty-seven percent of the patients had
stage I disease, 38% were stage II, 27% were stage III
and 8% were stage IV. The two stage IV patients wereTable 1 Patient and treatment characteristics
Characteristics No of patients (%)










Prior to SBRT 4 (15)
Post SBRT 6 (23)
None 16 (62)
Median PTV (range), cm3 21.48 (6.1-85.09)
Radiosurgery technique
Truebeam IMRS 1 (4)
Cyberknife – SBRT 11 (42)








36/3 4 (15)treated with SBRT with palliative intent. Fourteen patients
(54%) had locally-advanced disease extending into adjacent
vascular structures rendering them unresectable, whereas
12 (46%) had resectable disease but either wished not to
undergo surgical resection or were deemed poor surgical
candidates due to their co-morbidities. Four patients (15%)
received neoadjuvant chemotherapy, 6 patients (23%) re-
ceived chemotherapy in the adjuvant setting, and 16 (62%)
patients did not receive any chemotherapy. Immediately
prior to receiving SBRT, 11 patients presented with ab-
dominal pain, 5 with back pain, 5 with anorexia, 9 with
weight loss, 11 with jaundice, and 2 with nausea.
Treatment planning and delivery
All patients were evaluated in a multi-disciplinary setting
by surgical oncologists, radiation oncologists and medical
oncologists to determine treatment recommendations
based on tumor size, location, and extent of local disease.
Patients were treated with Trilogy-Intensity Modulated Ra-
diosurgery (IMRS) (Varian Medical Systems Inc., Palo Alto,
CA), TrueBeam™-Intensity Modulated Radiosurgery (IMRS)
(Varian Medical Systems, Palo Alto, CA) or Cyberknife ro-
botic radiosurgery system (Accuray Inc., Sunnyvale, CA).
Tumor movement as a result of respiration was managed
with Synchrony respiratory tracking system (Accuray Inc.,
Sunnyvale, CA) with Cyberknife radiosurgery and Real-
time Position Management Respiratory gating system
(Varian Medical Systems Inc., Palo Alto, CA) with Trilogy
IMRS and TrueBeam™ IMRS. All patients underwent 4D
CT simulation to tract tumor motion, and gating was used
on patients with >0.5 cm movement.
All patients treated with SBRT had endoscopically or
percutaneously placed gold fiducials (2–4) placed in or
near the tumor. Approximately 1 week after fiducial
placement, a 4-dimensional CT (4D CT) of the abdomen
with intravenous contrast was performed with the pa-
tient in the treatment position. For a precise and repro-
ducible position, patients were immobilized with a
customized Alpha Cradle (Smithers Medical Products,
North Canton, OH) for Cyberknife or BodyFix™ patient
positioning systems (Medical Intelligence Corporation,
Pasadena, CA) for Trilogy-IMRS.
The prescription dose and fractionation for each pa-
tient’s treatment regimen were determined by tumor size,
location, goals of treatment, and patient’s performance sta-
tus. A three-dimensional margin of 2 mm was added to
the gross tumor volume to determine the planning target
volume as shown in Figure 1. We prioritized limits of the
maximum doses to critical structures such as small bowel,
liver and stomach to ensure patient safety over optimal
PTV coverage, assessed on a case-by-case as described in
detail in a previous publication [12]. The median dose and
range of doses to the small bowel, kidneys, liver, and spinal
cord are listed in Table 2.
Figure 1 Axial view of a stereotactic radiosurgery plan via TrueBeam™-IMRS (Varian Medical Systems, Palo Alto, CA) delivering 36 Gy
given in 3 fractions to an 88 year old female. PTV is shown in red. Blue colorwash outline shows 80% prescribed isodose line. Critical
structures are outlined as follows: kidneys (yellow), liver (orange), bowels (brown), and spinal cord (blue).
Kim et al. Radiation Oncology 2013, 8:240 Page 3 of 8
http://www.ro-journal.com/content/8/1/240Each patient was evaluated at the delivery of each SBRT
fraction and 30 days after completion of treatment. Beyond
30 days, patients underwent regular follow-up by a mem-
ber of the multidisciplinary team. Response to treatment
was assessed by radiologists’ interpretation of contrast-
enhanced CT scans or PET-CT obtained 2 to 3 months
after completion and every 3 months until disease progres-
sion or death. For some patients, CA19-9 levels were also
obtained at follow-up as well. When local progression was
suspected but was questionable based on available imaging,
clinical examination or laboratory values, biopsy was
conducted. Improvement in any pre-treatment symptoms
was based on clinical follow-up notes.
The primary endpoints of our study were local control
(LC), overall survival (OS), symptom relief, acute and late
toxicities, cause specific survival (CSS) and freedom from
metastatic disease (FFMD). Local control was evaluated
only in patients with at least one follow-up imaging, and
local control was defined as stable or decrease in size
byradiology report of CT or PET-CT scans with no new as-
sociated symptoms. Toxicities were scored according to
the RTOG/EORTC grading criteria. Kaplan-Meier wasTable 2 Normal tissue dose constraints used for
treatment planning
Critical structure Median maximum dose (Range)
Liver 10.7 (4.1-24.5)
Right kidney 4.4 (1.7-12)
Left kidney 3.0 (0.7-12.9)
Small intestine 16.9 (10.4-29.9)
Spinal cord 3.8 (1.1-8.1)used to estimate OS, LC, CSS and FFMD [13]. Univariate
Cox regression analysis was conducted to identify signifi-
cant predictors of the above outcomes [14]. Factors in-
cluded in the Cox regression included target volume, age,
sex, KPS, stage, fraction size, number of fractions, prescrip-
tion dose, minimum dose, maximum dose, and whether or
not the patient received chemotherapy.Treatment characteristics
The median SBRT dose was 24 Gy (24-36 Gy) prescribed
to the 80% isodose line for Cyberknife, the 89% isodose
line (80-93%) for Trilogy-IMRS, and 24 Gy prescribed to
the 80% isodose line for TrueBeam™. Most patients (58%)
received a single dose of 24 Gy, one patient received a sin-
gle fraction of 22 Gy, one patient received 25 Gy, and the
rest received 24-36 Gy in 2-3 fractions (Table 1). The most
common fractionation schedule was 30-36 Gy given in 3
fractions, as this resulted in acceptable toxicities with the
intended local control outcome in our experience. In gen-
eral, the prescription doses were similar between defini-
tively treated resectable and unresectable tumors.Chemotherapy
For patients receiving chemotherapy (n=13), gemcitabine
was used in all cases. Four patients (15%) received
chemotherapy in the neoadjuvant setting prior to under-
going SBRT, 6 (23%) patients received chemotherapy in
the adjuvant setting, and 16 (62%) patients received no
chemotherapy as they were unfit for systemic therapy
based on medical co-morbidities.
Figure 3 Local control for all patients from time of SBRT.
Median LC was 11.5 months. Six-month and 12-month actuarial LC
rates were 60.1% and 41.2%, respectively.
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The median age of patients was 86 (80–91) with a median
follow-up of 11.6 months (3.5-24.6) from SBRT. Seventy-
seven percent of patients (20/26) had follow-up imaging
available for review. The median planning target volume
was 21.48 cm3 (6.1-85.09 cm3). Most tumors exhibited
minimal movement, and thus only 20% of the patients re-
quired gating. The median OS from time of SBRT was
7.6 months; 6-month OS was 65.4% and 12-month OS
was 34.6% (Figure 2). Median LC was 11.5 months and 9
patients eventually developed local recurrence based on
imaging, yielding a 6-month and 12-month actuarial local
control of 60.1% and 41.2%, respectively (Figure 3). We
did not identify any statistically significant independent
predictors for LC; however, there was a trend for im-
proved LC with prescription dose greater than 20 Gy (p =
0.063). Patients with resectable disease did not have sig-
nificantly better local control (p=0.366) or overall survival
(p=0.822) than those who were unresectable. Patients who
received chemotherapy did not have improvement in LC
(p=0.14), OS (0.71) or FFMD (0.15). The median time of
freedom from distant metastases was 8.4 months with a 6-
month and 12-month actuarial FFMD of 62.0% and 41.4%,
respectively (Figure 4). Overall, 9 patients (47%) had local
failures, 11 (58%) had distant metastasis, and 7 (37%) had
both. The most common site of distant metastasis was the
liver (50%). The median cause specific survival was
6.3 months with a 6-month and 12-month actuarial CSS
of 53.8% and 23.1%, respectively (Figure 5). Only one pa-
tient was unable to complete treatment due to intractable
pain, and there were no acute or late ≥ grade 3 toxicities.Figure 2 Overall survival for all patients from time of SBRT. The media
and 34.6%, respectively.Symptom relief was achieved in 8/10 patients who ini-
tially presented with abdominal pain (median time to re-
sponse: 1 month), 3/4 patients with back pain (3 mo), 4/6
patients with anorexia (1.4 mo), 5/9 patients with weight
loss (1 mo), 6/9 patients with jaundice (0.8 mo), and 2/2 pa-
tients with nausea (1.4 mo). Patients with weight loss were
considered to have relief once patient stopped losing add-
itional weight since completing treatment. Three patientsn OS was 7.6 months. Six-month and 12-month OS rates were 65.4%
Figure 4 Time to distant failure for all patients. The overall
median time of freedom from distant metastases was 8.4 months
with a 6-month and 12-month actuarial rates of 62.0% and
41.4%, respectively.
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ger required narcotic pain medication.
Discussion
The incidence of pancreatic cancer increases with age with
60% of patients presenting over the age of 65. While sur-
gery is the only treatment offering the possibility of cure,
only 9-15% of patients are eligible for potentially curativeFigure 5 Cause specific survival. The overall median CSS was 6.3 month
23.1%, respectively.resection [2]. Chemotherapy and/or radiotherapy are often
the treatment of choice for patients with locally advanced
or metastatic disease that is not amenable to surgical re-
section. Very elderly patients, however, may have signifi-
cant comorbidities that preclude surgery, chemotherapy,
or a protracted course of external beam radiation therapy.
For these patients, stereotactic body radiotherapy (SBRT)
is emerging as a promising new modality.
Multiple studies have found that age alone is not a
contraindication to pancreatic resection [5,15,16]; how-
ever, both morbidity and mortality rates following pan-
creatic resection increase with advanced age. Elderly
pancreatic cancer patients who undergo the Whipple re-
section have higher rates of postoperative complications
such as delayed gastric emptying, pancreaticojejunal leak,
sepsis, biliary leak, gastrointestinal tract bleeding, and
intra-abdominal hemorrhage [17]. One study found that
among patients who underwent pancreaticoduodenectomy,
octogenarians had a mortality rate of 4.1% and a complica-
tion rate of 52.8% whereas these rates were 1.7% and 41.6%,
respectively for younger patients [18]. Other conflicting
studies have found that age did not significantly influ-
ence perioperative complications and mortality among
pancreaticoduodenectomy patients [5,19]. However,
the latter findings could be influenced by the stringent
patient selection process applied to elderly patients
chosen to undergo surgical resection.
Gemcitabine has been the first-line therapy for advanced
pancreatic cancer for over the past decade [20], and Oettle
et al. have shown that postoperative gemcitabine signifi-
cantly delays disease recurrence after complete resections with a 6-month and 12-month actuarial rates of 53.8% and
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[21]. In a study of 68 patients, Matsumoto et al. found that
low-dose gemcitabine may improve the prognosis of eld-
erly patients (≥65) with unresectable pancreatic cancer
compared to best supportive care (median survival 7.6 vs.
2.3 months) [6]. Disease progression occurred in 33% of
patients and was stable in 53% of patients, while 15 pa-
tients had grade 3 or 4 toxicities. Another study of 30
patients aged ≥75 who underwent gemcitabine-based
chemotherapy for advanced pancreatic cancer found a
slightly higher median survival of 9.1 months. Disease
control was obtained in 57% of patients, and grade 3 neu-
tropenia was seen in 23% of patients with no grade 4 tox-
icities [22]. The literature on the efficacy of adjuvant
chemoradiation therapy in elderly patients is somewhat
limited. One retrospective series of elderly patients (de-
fined as age ≥75) with pancreatic cancer treated with
chemoradiation after pancreaticoduodenectomy, however,
did show that elderly patients had improved 2-year sur-
vival with trimodality therapy compared with surgery
alone (49.0% vs. 31.6%) [23].
We sought to evaluate the clinical feasibility of SBRT for
the treatment of advanced pancreatic adenocarcinoma in
octogenarians. Studies from Stanford University Hospital
have suggested that SBRT for unresectable pancreatic
adenocarcinoma is effective for local control but requires
caution against the associated risk of toxicity [11,24,25].
Chang et al. reported that among 77 patients with
unresectable pancreatic adenocarcinoma who received
25 Gy in 1 fraction, freedom from local progression (FFLP)
rates at 6 months and 12 months were 91%/84% and over-
all survival rates at 6 and 12 months were 56%/21%. Me-
dian follow-up was 6 months and rates of grade ≥3
toxicity was 9% (7/17) [11]. Another Stanford study
reported that among 16 patients with locally-advanced
non-metastatic pancreatic adenocarcinoma, a single frac-
tion of 25 Gy SBRT with gemcitabine resulted in good
local control but significant late GI toxicities [26]. The
overall survival at 1 year in this study was 50% with a me-
dian follow-up time of 9.1 months and 12.5% (2/16)
grade ≥3 toxicity rate. Another series found SBRT to be
feasible for the treatment of post-operative and advanced
pancreatic adenocarcinoma with minimal grade ≥ 3 toxicity
[12,27]. Our study confirms the feasibility, tolerability, and
safety of SBRT for the treatment of primary or recurrent,
locally-advanced or limited metastatic and unresectable
cancers in the very elderly.
All local recurrences in this study were assessed by the
radiologist’s report of the follow-up contrast-enhanced CT
or PET-CT scans, but this presumes that the images are
accurate in assessing local disease state. A recent study by
Katz et al. studied the rate at which neoadjuvant chemo-
therapy or chemoradiation is associated with a reduction
in the size or stage of borderline resectable tumors in 129patients [28] with pancreatic cancer. CT scans obtained
pre and post surgery were reviewed by faculty-level gastro-
intestinal radiologist to determine changes in tumor size
or stage using modified Response Evaluation Criteria in
Solid Tumors (RECIST) criteria. For 3/23 (13%) patients,
there was a significant difference between the interpret-
ation of CT images and intraoperative assessment. They
were assessed as having stable disease per radiology; how-
ever, the operating surgeon found them to have locally ad-
vanced disease progression. In general, they concluded that
there is no association between RECIST response and me-
dian OS duration. Similarly, we propose that CT or PET-
CT images alone without a biopsy may also be less accurate
in gauging local recurrence. For instance, one of our patients
in a different study treated with definitive chemoradiation
was assessed as having local recurrence per imaging report
and subsequently underwent pancreaticoduodenectomy.
This patient, however, was found to have a complete patho-
logic response. Therefore, our local control or local recur-
rence reported in our follow-up images may or may not
reflect the true disease extent.
We previously reported 6-month and 1-year FFLP rates
for metastatic, recurrent, and unresectable groups of 40%/
40%, 56%/18.8%, and 63.4%/38%, respectively [12]. Our
current study showed comparable rates with an overall 6-
month LC of 60.1% and 1-year LC of 34.6%. We have also
previously reported 6-month and 1-year FFLP rates of
94.7%/66% in a series of 24 patients with resected pancre-
atic carcinomas and close or positive margins [27] and
overall FFLP rates at 6 months and 1 year of 100%/70.7%
among 12 patients who had a Whipple with close margins
(≤2 mm) [12]. One factor that may have contributed to
our lower local control rate in this study is that we had a
higher proportion of patients with locally-advanced
adenocarcinoma. Therefore, it is not surprising that our
overall LC rates were slightly worse than those reported in
patients with resected disease, who had a better perform-
ance status, younger age, and perhaps less of a disease bur-
den. Our results are also inferior to those reported by
Chang et al. [11], who reported FFLP rate of 6-months
and 12-months of 91% and 84%, respectively. This may be
partially accounted for by the shorter median follow-up
time of 6 months in that study compared to 11.6 months
in our study. Other contributing factors may be the signifi-
cantly higher proportion of patients (96%) in Chang et al.’s
study who underwent chemotherapy, and the higher pro-
portion of patients in our study who presented with re-
gional lymph node involvement (at least 44%, compared
with 19% in Chang et al.).
In Rwigema et al.’s study, which reported outcomes in
71 patients with locally-advanced pancreatic adenocarcin-
oma treated to a median dose of 24 Gy with 94% of the pa-
tients receiving a single fraction of 24 Gy, median FFMD
was 2.8 months, 3.1 months, 3.0 months, and 9.7 months
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respectively [12]. The median time to distant metastases
was similar in our study at 8.4 months.
Our median OS from time of SBRT was 7.9 months,
which is comparable to the 10.3 months reported by
Rwigema et al. [12]. Our 6-month and 12-month actuar-
ial OS rates were 65.4%/34.6%, which is comparable to
57.4%/30.2% reported by Rwigema et al. [12] and 56%/
21% in the Stanford study by Chang et al. [11], as well as
previously published series of locally-advanced pancre-
atic adenocarcinoma [29,30].
SBRT was generally well-tolerated in this study. Only
one patient was unable to complete treatment due to in-
tractable pain, and there were no acute or late ≥ grade 3
toxicities. No patients had stenosis, ulceration, or perfor-
ation of bowel compared with 12% ulceration, 4% sten-
osis, and 1% perforation observed by Chang et al. [11].
Schellenberg et al. observed a significantly higher rate of
late GI toxicities, including one grade 4 duodenal perfor-
ation [26]. Our study also observed lower toxicity rates
than chemotherapy-only studies [5,23]. The lower tox-
icity rates seen in our study could be due to the use of
fractionated treatments in 9 (35%) of our patients as op-
posed to the single fraction of 25 Gy that patients in
Chang et al.’s study received, although no studies have
compared single versus multiple fraction regimens. In
addition, most of our patients did not receive chemo-
therapy, which could account for the decreased rate of
toxicity. However, since all patients died within 2 years,
the assessment of late toxicities in our study is likely
limited as there may not have been enough time for
these toxicities to manifest. We also showed that SBRT
is effective in achieving symptom relief. Nine out of 11
patients who initially presented at the time of SBRT with
abdominal pain and 3/5 patients who presented with
back pain reported symptom relief after SBRT, which is
comparable with the 13/16 patients in Rwigema et al.’s
study who presented with symptoms of pain and
reported complete pain relief shortly after SBRT [12]. In
addition, we achieved symptom relief for most patients
who presented with anorexia, weight loss, jaundice, or
nausea. Further studies with larger sample size and lon-
ger follow-up may be warranted to perform more de-
tailed assessment of pain control or symptom palliation,
especially in patients treated with palliative intent.
Based on our experience, patient selection for definitive
SBRT among octogenarians should take into account fac-
tors such as resectability, comorbidities that may compli-
cate surgery, and potential symptomatic relief. However,
one should note the small number of patients in this study
when interpreting and applying our data. In select octoge-
narians who have either unresectable locoregional disease
or resectable disease with comorbidities precluding sur-
gery, we recommend definitive SBRT +/- gemcitabine.Conclusions
In an elderly population with co-morbidities and poor
performance status that frequently preclude surgical
management, SBRT is feasible, safe and effective. SBRT
is a promising alternative to EBRT, offering a more con-
venient treatment regimen in a shorter overall treatment
time while being better tolerated by patients. A pro-
spective trial is currently underway to assess the efficacy
of this approach.
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